Chemomab Therapeutics Future Growth
Future criteria checks 0/6
Chemomab Therapeutics's earnings are forecast to decline at 14.8% per annum. EPS is expected to grow by 28.4% per annum.
Key information
-14.8%
Earnings growth rate
28.4%
EPS growth rate
Biotechs earnings growth | 35.7% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 26 Jul 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -26 | -23 | N/A | 3 |
12/31/2025 | N/A | -21 | -20 | N/A | 3 |
12/31/2024 | N/A | -16 | -16 | N/A | 3 |
3/31/2024 | N/A | -19 | N/A | N/A | N/A |
12/31/2023 | N/A | -24 | -24 | -24 | N/A |
9/30/2023 | N/A | -29 | -26 | -26 | N/A |
6/30/2023 | N/A | -33 | -26 | -26 | N/A |
3/31/2023 | N/A | -31 | -24 | -24 | N/A |
12/31/2022 | N/A | -28 | -20 | -20 | N/A |
9/30/2022 | N/A | -24 | -18 | -18 | N/A |
6/30/2022 | N/A | -19 | -15 | -15 | N/A |
3/31/2022 | N/A | -16 | -15 | -15 | N/A |
12/31/2021 | N/A | -12 | -13 | -12 | N/A |
9/30/2021 | N/A | -9 | -11 | -11 | N/A |
6/30/2021 | N/A | -8 | -9 | -9 | N/A |
3/31/2021 | N/A | -6 | -5 | -5 | N/A |
12/31/2020 | N/A | -6 | -5 | -5 | N/A |
9/30/2020 | N/A | 11 | 1 | 0 | N/A |
12/31/2019 | N/A | -7 | -7 | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2QV0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2QV0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2QV0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 2QV0's revenue is forecast to grow faster than the German market.
High Growth Revenue: 2QV0 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2QV0's Return on Equity is forecast to be high in 3 years time